RxDoctor Payments Data

Nicholas Kennedy, DO

Internal Medicine · Greenville, SCNPI 1588199335

Payments from drug & device makers

$750in general payments, 2019–2025

Across 26 payments — averaging $28.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$232
  • Novo Nordisk$197
  • Pfizer$124
  • Lilly USA, LLC$42
  • AstraZeneca$24
  • Dexcom, Inc.$23
  • plus $107 from 7 others

What the payments were for

  • Food & beverage$750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$750 in reported general payments places this provider in the 60th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$237,763
Medicare patients
413
Services billed
6,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$79,347
MounjaroTirzepatide51$54,850
OzempicSemaglutide35$53,166
JardianceEmpagliflozin20$26,953
RybelsusSemaglutide18$23,861
TrulicityDulaglutide19$19,493
JanuviaSitagliptin Phosphate12$18,688
MyrbetriqMirabegron20$9,491
PremarinEstrogens, Conjugated14$6,117
PaxlovidNirmatrelvir/Ritonavir14$4,288
Atorvastatin Calcium328$2,810
Pregabalin43$2,622
Wixela InhubFluticasone Propion/Salmeterol23$2,472
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,471
SynthroidLevothyroxine Sodium37$2,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$124$89,752107 claims
Novo NordiskOzempic, Rybelsus$197$77,02753 claims
Lilly USA, LLCMounjaro, Trulicity$42$74,34470 claims
Astellas Pharma US IncMyrbetriq$16$9,49120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →